PuraPharm Corporation Limited
HKEX:1498.HK
0.66 (HKD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 406.859 | 448.069 | 659.592 | 601.815 | 695.879 | 745.503 | 591.566 | 535.986 | 473.9 | 366.352 | 342.303 |
| Cost of Revenue
| 192.013 | 187.483 | 237.741 | 233.126 | 298.289 | 290.603 | 195.708 | 187.182 | 168.168 | 134.241 | 123.086 |
| Gross Profit
| 214.846 | 260.586 | 421.851 | 368.689 | 397.59 | 454.9 | 395.858 | 348.804 | 305.732 | 232.111 | 219.217 |
| Gross Profit Ratio
| 0.528 | 0.582 | 0.64 | 0.613 | 0.571 | 0.61 | 0.669 | 0.651 | 0.645 | 0.634 | 0.64 |
| Reseach & Development Expenses
| 14.987 | 20.205 | 23.95 | 20.778 | 33.484 | 26.367 | 19.284 | 18.115 | 15.603 | 16.133 | 16.142 |
| General & Administrative Expenses
| 171.52 | 157.716 | 168.143 | 152.966 | 224.62 | 174.605 | 173.204 | 130.849 | 106.097 | 72.762 | 74.207 |
| Selling & Marketing Expenses
| 91.658 | 157.383 | 220.006 | 210.539 | 226.212 | 229.995 | 191.753 | 154.38 | 140.214 | 99.176 | 101.94 |
| SG&A
| 249.135 | 303.52 | 380.283 | 352.789 | 425.352 | 447.021 | 398.74 | 308.381 | 259.59 | 180.204 | 181.651 |
| Other Expenses
| -2.307 | -1.361 | -51.175 | 0.849 | -34.004 | 20.66 | 9.344 | 7.78 | 5.567 | -2.307 | 0 |
| Operating Expenses
| 266.429 | 325.086 | 404.233 | 373.567 | 458.836 | 406.921 | 369.11 | 301.516 | 256.188 | 177.431 | 176.633 |
| Operating Income
| -51.583 | -64.5 | 17.618 | -4.878 | -61.246 | 9.245 | -2.882 | 40.423 | 46.142 | 51.907 | 37.566 |
| Operating Income Ratio
| -0.127 | -0.144 | 0.027 | -0.008 | -0.088 | 0.012 | -0.005 | 0.075 | 0.097 | 0.142 | 0.11 |
| Total Other Income Expenses Net
| -50.584 | -54.682 | -134.81 | 45.095 | -154.904 | 17.286 | 13.213 | -1.756 | -6.008 | -9.577 | -7.876 |
| Income Before Tax
| -102.167 | -119.182 | -117.192 | 40.217 | -216.15 | 26.531 | 10.331 | 38.667 | 40.134 | 42.33 | 29.69 |
| Income Before Tax Ratio
| -0.251 | -0.266 | -0.178 | 0.067 | -0.311 | 0.036 | 0.017 | 0.072 | 0.085 | 0.116 | 0.087 |
| Income Tax Expense
| 3.769 | 1.032 | 4.685 | 8.507 | 11.108 | 5.725 | 8.442 | 6.505 | 11.676 | 7.823 | 3.399 |
| Net Income
| -106.081 | -120.214 | -121.877 | 31.71 | -227.258 | 20.806 | 1.889 | 32.162 | 28.458 | 34.463 | 26.264 |
| Net Income Ratio
| -0.261 | -0.268 | -0.185 | 0.053 | -0.327 | 0.028 | 0.003 | 0.06 | 0.06 | 0.094 | 0.077 |
| EPS
| -0.27 | -0.3 | -0.31 | 0.086 | -0.82 | 0.084 | 0.008 | 0.14 | 0.15 | 74.54 | 0 |
| EPS Diluted
| -0.27 | -0.3 | -0.31 | 0.085 | -0.82 | 0.084 | 0.008 | 0.14 | 0.15 | 74.54 | 0 |
| EBITDA
| -2.992 | -15.839 | 67.757 | 42.748 | 5.509 | 44.839 | 21.896 | 55.7 | 59.142 | 65.226 | 49.368 |
| EBITDA Ratio
| -0.007 | -0.035 | 0.103 | 0.071 | 0.008 | 0.06 | 0.037 | 0.104 | 0.125 | 0.178 | 0.144 |